Effects of long-term monotherapy with metoprolol CR/XL on the progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure

Cardiovascular Drugs and Therapy

Volumn 16, Issue 5, 2002, Pages 443-449

  Morita, Hideaki ^a   Suzuki, George ^a   Mishima, Takayuki ^a   Chaudhry, Pervaiz A ^a   Anagnostopoulos, Petros V ^a   Tanhehco, Elaine J ^a   Sharov, Victor G ^a   Goldstein, Sidney ^a   Sabbah, Hani N ^a,b  

^a Henry Ford Heart/Vascular Institute   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

blockers; Heart failure; Ventricular function; Ventricular remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE COURSE; DOG; DOSE CALCULATION; DRUG MECHANISM; FIBROSING ALVEOLITIS; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HYPERTROPHY; LONG TERM CARE; MICROEMBOLISM; MONOTHERAPY; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; TIME;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CHRONIC DISEASE; DOGS; FEMALE; FIBROSIS; HEART DISEASES; HEART VENTRICLES; MALE; METOPROLOL; MODELS, ANIMAL; MYOCYTES, CARDIAC; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037001786     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022142620189     Document Type: Article

References (30)

1. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
2. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
3. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-1446.
4. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349-1355.
5. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997;349:375-380.
6. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90: 1765-1773.
7. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-2007.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
9. Sabbah HN, Shimoyama H, Kono T, et al. Effects of longterm monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-2859.
10. Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-H1384.
11. Weiss JL, Frederiksen JW, Weisfeldt ML. Hemodynamic determinants of the time-course of fall in canine left ventricular pressure. J Clin Invest 1976;58:751-760.
12. Dodge HT, Sandler H, Baxley WA, Hawley RR. Usefulness and limitations of radiographic methods for determining left ventricular volume. Am J Cardiol 1966;18:10-24.
13. Kono T, Sabbah HN, Stein PD, Brymer JF, Khaja F. Left ventricular shape as a determinant of functional mitral regurgitation in patients with severe heart failure secondary to either coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68:355-359.
14. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-1598.
15. Grossman W. Cardiac Catheterization and Angiography, 3rd ed. Philadelphia, PA: Lea & Febiger, 1986:293.
16. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99:1926-1935.
17. Sabbah HN, Kono T, Stein PD, Mancini GB, Goldstein S. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol 1992;263:H266-H270.
18. Borow KM, Lang RM, Neumann A, Carroll JD, Rajfer SI. Physiologic mechanisms governing hemodynamic responses to positive inotropic therapy in patients with dilated cardiomyopathy. Circulation 1988;77:635-637.
19. Burton AC. The importance of the shape and size of the heart. Am Heart J 1957;54:801-809.
20. Gould KL, Lipscomb K, Hamilton GW, Kennedy JW. Relation of left ventricular shape, function and wall stress in man. Am J Cardiol 1974;34:627-634.
21. Kono T, Sabbah HN, Rosman H, Alam M, Jafri S, Goldstein S. Left ventricular shape is the primary determinant of functional mitral regurgitation in heart failure. J Am Coll Cardiol 1992;20:1594-1598.
22. Sabbah HN, Kono T, Rosman H, Jafri S, Stein PD, Goldstein S. Left ventricular shape: A factor in the etiology of functional mitral regurgitation in heart failure. Am Heart J 1992;123:961-966.
23. Nass O, Rosman H, Al-Khaled N, et al. Relation of left ventricular chamber shape in patients with low (≤40%) ejection fraction to severity of functional mitral regurgitation. Am J Cardiol 1995;76:402-404.
24. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: A role for interstitial fibrosis. Mol Cell Biochem 1995;147:29-34.
25. Sabbah HN, Sharov VG, Goldstein S. Remodeling of the cardiac interstitium in the progression of heart failure. J Clin Basic Cardiol 1999;2:113-116.
26. Tanaka M, Ito H, Adachi S, et al. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res 1994;75:426-433.
27. Sabbah HN, Sharov VG, Gupta RC, Todor A, Singh V, Goldstein S. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. J Am Coll Cardiol 2000;36:1698-1705.
28. Goussev A, Sharov VG, Shimoyama H, et al. Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure. Am J Physiol 1998;275:H626-H631.
29. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1342-1345.
30. Lowes BD, Gilbert EM, Abraham WT, et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002;346:1357-1365.